Proactive Investors - Run By Investors For Investors

Two US approvals spell big business potential for Circassia

Circassia Pharmaceuticals PLC (LON:CIR) is a company focussed on treating patients with respiratory diseases which has just won two new significant US approvals.The approvals could unlock hundreds of millions of dollars of potential market share which could transform the business. Circassia CEO Steve Harris tells Proactive London how the products fit into the rest of the portfolio and why this hurdle is also important for patients suffering from COPD and CHD.
Circassia has several other asthma and COPD treatments in its pipeline including  AirNOvent – a portable system that uses electricity to make nitric oxide in turn to dilate blood vessels in the lungs.

 
View full CIR profile View Profile

Circassia Pharmaceuticals Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use